Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups

17 Sept 2018

Abstract excerpt

Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor combination for the treatment of serious infections caused by resistant gram-negative pathogens. Population pharmacokinetic (PopPK) models were built to incorporate pharmacokinetic (PK) data from five phase III trials in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), or nosocomial (including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30221827
DOI: 10.1111/cts.12585

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient SubgroupsPMID 30221827Read ↗

Update of clinical application in ceftazidime–avibactam for multidrug-resistant Gram-negative bacteria infectionsSemantic proximity Read ↗

Ceftazidime-avibactam Versus Tigecycline for the Treatment of Carbapenem-resistant Klebsiella Pneumoniae-induced Pneumonia in Critically Ill PatientsSemantic proximity Read ↗

Population pharmacokinetic modeling and Monte Carlo simulation-based dosing optimization of trimethoprim-sulfamethoxazole in critically ill patients.Semantic proximity Read ↗

A Real-World Pharmacovigilance Study of Ceftazidime/avibactam: Data Mining of the FDA Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read ↗

Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patientSemantic proximity Read ↗

Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.Semantic proximity Read ↗

Vancomycin Population Pharmacokinetic Models in Non- Critically Ill Adults Patients: a scoping reviewSemantic proximity Read ↗

Nonlinear Mixed-Effects and Full Bayesian Population Pharmacokinetic Analysis of Ceftolozane–Tazobactam in Critically Ill PatientsSemantic proximity Read ↗

Individualized Meropenem Dosing in CRRT Patients: Development and Validation of a Machine Learning-Based Decision Support ToolSemantic proximity Read ↗

Rising resistance to linezolid among critically ill patients calls for model-informed precision dosing in the empirical settingSemantic proximity Read ↗

I n vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complexSemantic proximity Read ↗

Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.